Eton Pharmaceuticals (ETON)
Develops and commercializes rare-disease therapies through product launches and rights agreements.
Something off on this page? Send us feedback.
Develops, acquires, and commercializes rare-disease therapies through a single reportable segment. Product launches and commercialization-rights agreements expand a focused portfolio supported by specialized sales and marketing.
Develops, acquires, and commercializes rare-disease therapies through a single reportable segment. Its commercial portfolio includes KHINDIVI, INCRELEX, and HEMANGEOL; the sale of hospital-product rights sharpened the business around rare diseases.
The portfolio grows through product launches and commercialization-rights agreements. U.S. commercialization rights for HEMANGEOL support that model, while the IMPAVIDO rights agreement is scheduled to take effect and is not yet a current commercial product.
Execution depends on FDA approvals, product-rights agreements, and a small specialized sales-and-marketing organization. The operating model is built around commercial execution for a focused rare-disease portfolio.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 14, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $60 | Target: $68 |
| Aug 14, 2026 | H.C. Wainwright | Target | Target: $65 | Target: $70 |
| Aug 11, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $57 | Target: $65 |
| Jul 28, 2026 | Craig-Hallum | Reiterate | Rating: —Target: $15 | Target: $62 |
| Jul 16, 2026 | Canaccord Genuity | Target | Target: — | Target: $60 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $26.8M · Total debt $29.0M · Total assets $115.8M · Shareholders' equity $46.6M
- Revenue
- $37.6M
- Operating income
- $12.8M
- Net income
- $11.6M
No dividends on record.
| Institutions | ≈ 69.35% | 19.82M shares | |
|---|---|---|---|
| 172 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 4.99% | 1.43M shares | |
| 9 holders · as of Aug 31, 2026 | |||
| Other | ≈ 25.66% | 7.34M shares | |
| remainder | |||
28.58M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Opaleye Management Inc.Institution | 10.01% | 2.86M | as of Jun 30, 2026 |
Ecor1 Capital, LLCInstitution | 7.60% | 2.17M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.63% | 1.90M | as of Jun 30, 2026 |
Nantahala Capital Management, LLCInstitution | 4.11% | 1.18M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.42% | 976,570 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 28, 2026 | Paul V. Maier | director | −50,000 | $59.07 |
| Aug 24, 2026 | David Krempa | officer: Chief Business Officer | −25,000 | $65.07 |
| Aug 20, 2026 | Sean Brynjelsen | director, officer: President & CEO | −91,022 | $60.70 |
| Aug 19, 2026 | Sean Brynjelsen | director, officer: President & CEO | −8,978 | $62.65 |
| Jul 14, 2026 | Opaleye Management Inc. | 10 percent owner | −28,315 | $37.54 |
- Bausch Health
Wilson disease copper-chelation alternative to zinc maintenance
- BioMarin
PKU enzyme therapy in the same metabolic-disease care pathway
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Eton Pharmaceuticals | $56.54 | +2.23% | $1.52B | 143.8 | 37.3 | 14.3 | +98.6% |
| Bausch Health | $5.71 | +1.15% | $2.11B | — | 1.3 | 0.2 | +11.2% |
| BioMarin | $63.79 | −0.42% | $12.38B | 164.3 | 10.4 | 3.6 | +20.0% |
| Median | 164.3 | 5.8 | 1.9 | +15.6% |